SCHEMBL198289

SCHEMBL198289

O=C(Cl)c1c(I)ccnc1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 2/20 0.32
USP2 O75604 2/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 2/20 0.32
HSP90AA1 P07900 2/20 0.32
HPGD P15428 2/20 0.32
ALOX15 P16050 2/20 0.32
SLC6A2 P23975 2/20 0.32
MAPK1 P28482 2/20 0.32
HTT P42858 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HIF1A Q16665 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
APP P05067 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197777 0.82 KDM4E (0.37) ALDH1A1KDM4ELMNATP53SMN1; SMN2
SCHEMBL26618917 0.78 NAPRT (0.36) ALDH1A1KDM4EALOX15KMT2A
SCHEMBL197858 0.76 CA12 (0.46) ALDH1A1KDM4ELMNAHPGDALOX15
SCHEMBL31005749 0.74 POLB (0.34) ALDH1A1LMNAHPGDHTTSMN1; SMN2
SCHEMBL7434133 0.70
SCHEMBL15662511 0.69
SCHEMBL1989103 0.68 SMN1; SMN2 (0.46) ALDH1A1KDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL28280472 0.67 KDM4E (0.38) ALDH1A1KDM4ELMNAALOX15SMN1; SMN2
SCHEMBL16995132 0.67 LMNA (0.36) ALDH1A1KDM4EMEN1LMNAHTT
SCHEMBL10762405 0.65 DPP4 (0.52) ALDH1A1KDM4ELMNAALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
CN-101248059-A Substituted amide derivatives as protein kinase inhibitors AMGEN INC (US) 2008-08-20 CN disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET ALDH1A1 76/4885KDM4E 3651/4885MEN1 899/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET ALDH1A1 58/4885KDM4E 3048/4885MEN1 755/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET ALDH1A1 76/4885KDM4E 3651/4885MEN1 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.